Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Amir Ishaq KhanSarah P PsutkaDattatraya H PatilGordon HongMilton A WilliamsMehmet Asim BilenAarti SekharHaydn T KissickVikram M NarayanShreyas S JoshiKenneth OganViraj A MasterPublished in: Cancer (2022)
Body composition and sarcopenia (a deficiency in skeletal musculature) have been shown to affect outcomes in cancer. We found that sarcopenic patients had poor survival in comparison with nonsarcopenic patients in the setting of metastatic renal cell carcinoma (mRCC). Patients with both elevated inflammation and sarcopenia had the poorest survival. Sarcopenia is an objective measure of nutrition that can assist in therapeutic counseling and decision-making for individualized treatment in mRCC.
Keyphrases
- metastatic renal cell carcinoma
- body composition
- end stage renal disease
- skeletal muscle
- ejection fraction
- chronic kidney disease
- newly diagnosed
- decision making
- peritoneal dialysis
- prognostic factors
- oxidative stress
- physical activity
- resistance training
- patient reported outcomes
- squamous cell carcinoma
- community dwelling
- adipose tissue
- insulin resistance
- young adults
- hiv infected
- human immunodeficiency virus
- replacement therapy